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The physiological response of the human body to several diseases can be reflected by the
metabolite pattern in biological fluids. Cancer, like other diseases accompanied by metabolic
disorders, causes characteristic effects on cell turnover rate, activity of modifying enzymes,
and RNA/DNA modifications. This results in an altered excretion of modified nucleosides and
biochemically related compounds. In the course of our metabolic profiling project, we screened
24-h urine of patients suffering from lung, rectal, or head and neck cancer for previously
unknown ribosylated metabolites. Therefore, we developed a sample preparation procedure
based on boronate affinity chromatography followed by additional prepurification with
preparative TLC. The isolated metabolites were analyzed by ion trap mass spectrometry (IT
MS) and Fourier transform ion cyclotron resonance mass spectrometry (FTICR MS). IT MS was
applied for LC-auto MS3 screening runs and MSn(n  4 –6)  syringe pump infusion experiments,
yielding characteristic fragmentation patterns. FTICR MS measurements enabled the calcula-
tion of corresponding molecular formulae based on accurate mass determination (mass
accuracy: 1–5 ppm for external and sub-ppm values for internal calibration). We were able to identify
22 metabolites deriving from cellular RNA metabolism and related metabolic pathways like histidine
metabolism, purine biosynthesis, methionine/polyamine cycle, and nicotinate/nicotinamide metabo-
lism. The compounds 1-ribosyl-3-hydroxypyridinium, 1-ribosyl-pyridinium, and 3-ribosyl-1-methyl- l-
histidinium as well as a series of ribosylated histamines, conjugated to carboxylic acids at the
N-position were found as novel urinary constituents. The occurrence of the modified nucleosides
2-methylthio-N6-(cis-hydroxyisopentenyl)-adenosine, 5-methoxycarbonylmethyl-2-thiouridine,
N6-methyl-N6-threonylcarbamoyladenosine, and 2-methylthio-N6-threonylcarbamoyladenosine in
human urine is verified for the first time. (J Am Soc Mass Spectrom 2008, 19, 1500 –1513) © 2008
American Society for Mass SpectrometryThe clinical research for reliable biomarkers inearly diagnosis and therapy surveillance of can-cer diseases is a rapidly emerging field since
many of the presently applied marker compounds
show only unsatisfactory prediction values. Screening
the genomic profile (genomics) [1, 2] and the expressed
protein pattern (proteomics) [3, 4] for characteristic
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changes are well-defined concepts in clinical cancer
research. Recently, the metabolome, represented by the
end products of gene-/protein expression and the bio-
chemical phenotype of a cell or tissue, has experienced
increasing interest [5–7].
The corresponding research area of metabolomics is
defined as the comprehensive identification and quan-
tification of all metabolites of a biological system [8].
Considering the wide range of chemical and physical
properties of various metabolite classes, this analytical
scope is still challenging. A more viable aspect of the
metabolomics concept is the metabolic profiling ap-
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of a subset of metabolites belonging to a selected
metabolic pathway [8].
Possible targets for metabolic profiling related to
neoplastic cancer diseases are compounds originating
from cellular RNA metabolism. The resulting ribonu-
cleoside metabolites are released post-transcriptionally
due to stepwise enzymatic degradation of the polynu-
cleotide macromolecules. Whereas the common nucleo-
sides cytidine, uridine, adenosine, and guanosine are
recycled for intracellular RNA-rebuilding, their modi-
fied counterparts are quantitatively excreted from the
cell as metabolic endproducts. Altered levels of modi-
fied nucleosides in biological fluids have been demon-
strated in association with various types of cancer
[9–12]. This phenomenon is generally attributed to the
increased RNA turnover rate and activity of modifying
enzymes in tumor cells [13, 14]. Besides the quantitative
analysis of the nucleoside pattern, the search for previ-
ously unknown, cancer-specific modifications is a
promising approach. Dudley et al. identified the novel
nucleoside structure 5=-deoxycytidine in the urine of a
patient with terminal head and neck cancer [15]. In
urine of cancer patients in other stages of the disease
and of healthy volunteers, this modified nucleoside was
not detectable and thus might be directly related to the
tumor stage and development [5=-deoxycytidine could
not be detected in the analyzed urine samples of this
study].
Methods like high-performance liquid chromatogra-
phy (HPLC) with UV detection [16, 17] and capillary
electrophoresis (CE) [18] have been applied for the
analysis of ribonucleosides. Recently, the coupling of
HPLC with mass spectrometric detection via electros-
pray ionization ion trap mass spectrometry (ESI-IT MS)
[15, 19], ESI tandem MS [20, 21], and fast atom bom-
bardment (FAB) [22, 23] has been established. Sophisti-
cated mass spectrometric setups like ESI-oa-TOF MS
[24] and MALDI-TOF MS [25] have already proven to
be valuable tools for the structural elucidation of RNA
metabolites. To date, about 100 modified nucleoside
structures have been identified, originating from differ-
ent RNA species [26].
In general, the analysis of urinary metabolite pat-
terns has to be interpreted carefully because of various
possible interferences along the excretion pathway.
Biotransformation reactions in the bloodstream, liver,
and kidney as well as other endogenous influences (e.g.,
formation of secondary metabolites from endosymbi-
onic bacteria in humans) can affect and falsify the
metabolic profile. Consequently, when selecting uri-
nary compounds for cancer biomarker studies, both
structural identification of the metabolites and knowl-
edge of their biochemical origin are of utmost impor-
tance for the reliability of clinical prediction.
For this purpose, we developed a method for the
identification of ribosylated metabolites in the 24-h
urine of tumor patients suffering from lung, rectal, or
head and neck cancer. Structural elucidation wasachieved by combining accurate mass determination
via FTICR MS and characteristic fragmentation pat-
terns, generated by IT MS. The applied boronate affinity
chromatography generally isolates a broad spectrum of
cis-diol metabolites, mainly ribose conjugated. Besides
several RNA metabolites, we were able to identify
compounds originating from interconnected metabolic
pathways [27] like the histidine metabolism, the purine
biosynthesis, and the methionine/polyamine cycle as
well as from the nicotinate/nicotinamide metabolism.
Experimental
Urine Samples
The 24-h urine samples were obtained from the Depart-
ments of Radiation Oncology and Otorhinolaryngology
and Head and Neck Surgery at the University Hospital
Tübingen.
To minimize possible endo- and exogenous pertur-
bations on the urinary metabolite pattern, we defined
precise criteria for patient recruitment. The samples
from male and female patients suffering from lung (n
2, T2, T4), rectal (n  4, all T3), or head and neck cancer
(n  3, T3, 2x T4) were taken preoperatively with no
neoadjuvant hormonal, irradiation, or chemotherapy
applied. Patients taking immunomodulating drugs, an-
tibiotics, mistletoe preparations, virustatics, allopurinol,
and dipyridamole were not included in this study.
Pregnancy, immune mediated diseases, HIV, acute and
chronic hepatitis, chronic renal failure, acute infection
of the urinary tract as well as the patients’ participation
in a clinical drug trial also resulted in the exclusion from
the study. Particular nutrition aspects were not consid-
ered except for the documentation of smoking behavior.
The patients collected the urine over a period of 24 h,
using the UriSet24 (Sarstedt, Nümbrecht, Germany).
The obtained samples were immediately analyzed after
termination of the collection period.
Chemicals
Methanol for liquid chromatography (LiChrosolv,
hypergrade), methanol for affinity chromatography
(LiChroSolv, gradient grade), acetonitrile for prepara-
tive TLC (LiChrosolv, gradient grade), ammonium ac-
etate (extra pure), and formic acid (extra pure) were
purchased from Merck/VWR (Darmstadt, Germany).
Ammonium formate (puriss. p.a., for mass spectrome-
try) was obtained from Fluka (Taufkirchen, Germany).
Water was taken from an in-house double distillation
system.
Commercially available standards used as reference for
compound identification via retention time and/or IT
MSn fragmentation patterns were 2-hydroxypyridine, 3-
hydroxypyridine, 4-hydroxypyridine, N--acetylhistamine,
N6-methyladenosine (m6A), 1-ribosyl-4-carboxamido-5-
aminoimidazole (AICA riboside), adenylosuccinic acid
(sodium salt), imidazole-4-acetic acid (sodium salt), and
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many), N2,N2,7-trimethylguanosine acetate (m2,2,7G)
from Biolog (Bremen, Germany), pyridine from Gruess-
ing (Filsum, Germany), and 1-methyl-l-histidine, pur-
chased from Calbiochem/Merck (Nottingham, UK).
Extraction of Nucleosides and Structurally Related
Compounds from 24-h Urine
Previous to HPLC separation, the metabolites were
isolated from urine by cis-diol specific affinity chroma-
tography using affigel boronate (Biorad, Munich, Ger-
many) by a slightly modified version of the method
developed by Liebich et al. in 1997 [28]. A total of 300
mL 24-h urine was processed in single steps of 20 mL.
The samples were alkalinized to pH 8.8 with 2.5%
ammonia solution and then put on the column (500 mg
affigel boronate, column dimensions: 150  15 mm),
preconditioned with 45 mL ammonium acetate solu-
tion, pH 8.8, 0.25 M. Because of the high backpressure
from the affigel boronate material, compressed air was
applied throughout the extraction procedure to main-
tain a moderate flow rate. Nucleosides and other ribo-
sylated compounds were bound reversibly and specif-
ically at the 2=,3=-cis-diol group contained in the ribose
structure. After washing with 20 mL ammonium acetate
solution (pH 8.8, 0.25 M) and 6 mL methanol-water (2:8,
vol/vol), elution was carried out with 50 mL 0.2 M
formic acid in methanol-water (1:1, vol/vol). The col-
umn was washed with 25 mL methanol-water (2:8,
vol/vol) and reconditioned with 45 mL ammonium
acetate solution (pH 8.8, 0.25 M). This was repeated 15
times to an extracted end volume of 300 mL urine. The
collected elution solvent was removed using a rotary
evaporator and the residue was dissolved again in 1 mL
ammonium formate solution (pH 5.0, 5 mM).
Prepurification and Separation by Preparative TLC
For further prepurification of the highly concentrated
eluate, 300 L solution was put on a preparative TLC
plate (SIL RP-18W/UV254, 1 mm; Macherey-Nagel,
Düren, Germany). Chromatographic separation was
carried out over a total migration distance of 6 cm using
a solvent composition of acetonitrile-water (1:6, vol/
vol). The distance from starting line to solvent front was
subdivided into twelve 0.5 cm fractions (fraction 1 
0–0.5 cm, fraction 2  0.5–1.0 cm, . . .). The plate
material was separately scraped off and extracted twice
with 20 mL portions of methanol-water (3:2, vol/vol 
1% formic acid) in an ultrasonic bath. Solid impurities
were removed by centrifugation (3000g, 10 min, 20 °C).
The 12 extracts from the TLC plate fractions were
concentrated by rotary evaporation and the residues
were dissolved again in 1 mL ammonium formate
solution (pH 5, 5 mM). Ten microliters of these samples
were injected into the HPLC-MS system.Semipreparative HPLC for Isolation of
Selected Metabolites
Due to limitation of MS3 fragmentation in auto-LC MSn
runs, selected metabolites were isolated via semi-
preparative HPLC for IT MSn(n  4–6) syringe pump
infusion experiments. Therefore, a total of 250–300 L
of each TLC fraction was injected in portions of 50 L
into the LC-IT MS system. Compounds chosen for
additional mass spectrometric analysis were collected
in 1.5 mL Eppendorf tubes at the corresponding reten-
tion times using the same gradient system as developed
for the LC-auto MS3 runs (see text, LC-ESI-IT MS
section). The obtained metabolite solutions were also
used for high-resolution FT MS analysis.
LC-ESI-IT MS
The chromatographic separation of the urinary metab-
olites was performed on an Agilent 1100 Series HPLC
system (Agilent, Waldbronn, Germany) consisting of a
solvent degasser (G 1379 A), a binary capillary pump (G
1389), an autosampler (G 1313 A), a column oven (G
1316 A), and a DAD (G 1315 B). The chromatographic
system consisted of a Merck LiChroCART Superspher
100 RP-18 endcapped column (125  2.0 mm i.d., 4 m;
Merck, Darmstadt, Germany) and a solvent system of 5
mM ammonium formate buffer, pH 5.0, and methanol-
water (3:2, vol:vol 0.1% formic acid). The column was
operated at 25 °C. The flow rate was set to 125 L/min
using a gradient as described by Kammerer et al. [19].
The LC system was coupled to a Bruker Esquire HCT-
ion trap mass spectrometer (Bruker Daltonics, Bremen,
Germany), equipped with an ESI source and operated
in positive ion detection mode.
For LC-auto MS3 runs, the capillary voltage was set
to 4 kV, the drying gas temperature in the electrospray
source was set to 350 °C, the nebulizer gas was set to 45
psi, and the drying gas to 9.0 L/min. The data were
acquired in standard enhanced scan mode (8100
m/z per s) over a mass range 200–600 Da. Pre-
viously identified major nucleoside compounds (e.g.,
1-methyladenosine, 1-methylinosine, and N2,N2-
dimethylguanosine) were excluded from MSn selec-
tion for sensitive detection of minor compounds,
coeluting in the HPLC separation.
Syringe pump (Cole Parmer, Vernon Hills, IL) infu-
sion experiments for MSn analysis were carried out at a
flow rate of 300 L/h. The capillary voltage was set to
4 kV, the drying gas temperature in the electrospray
source was set to 270 °C, the nebulizer gas was set to 18
psi, and the drying gas to 6.0 L/min. The data were
acquired in standard enhanced scan mode (8100 m/z per
second) over a mass range 30–500 Da. All IT MS
measurements were performed using the Bruker Es-
quire Control software, version 5.1. For postprocessing,
Bruker Data Analysis version 3.1 was applied.
revio
1503J Am Soc Mass Spectrom 2008, 19, 1500–1513 METABOLITE IDENTIFICATION VIA FT MS AND IT MSESI-FTICR MS
ESI-FTICR MS measurements were carried out on a
passively shielded 4.7 T APEX II ESI-FTICR mass spec-
trometer (Bruker Daltonics, Bremen, Germany). For
data acquisition and postprocessing, the XMASS ver-
sion 5.0.10 software (Bruker Daltonics) was used. High-
resolution mass spectra were generated in the positive
ionization mode with a 60° off-axis grounded capillary
sprayer needle (Analytica of Branford Inc., Branford,
CT). The capillary exit voltage was adjusted to 15–25 V.
For internal and external calibration, a homologous
series of polyethylene glycols (PEG 400) was used.
Samples were introduced via syringe pump (Cole
Parmer, Vernon Hills, IL) infusion at a flow rate of 80
L/h.
Results and Discussion
In the present study, we demonstrate the potential of
combined IT MSn and FT MS analysis for the structural
elucidation of ribosylated metabolites in the 24-h urine.
Figure 1 shows the chemical structures of newly dis-
covered metabolites in humans. To the authors’ best
knowledge, these derivatives have not been described
previously in literature.
For preliminary metabolite screening, we applied
auto-LC-IT MS3 runs [19] of the extracted urine
fractions obtained by preparative TLC purification.
Collision induced dissociation (CID) experiments en-
abled the generation of constant neutral loss (CNL)
chromatograms, displaying only those compounds
losing a defined functional group in the MS2 step
Figure 1. Identified structures of p(Figure 2).In nucleosides and other ribosylated metabolites,
this step is generally represented by the characteristic
decay of the neutral sugar moiety at the fragile
N-glycosidic bond. Loss of 132 Da therefore is a
strong indication for metabolites conjugated to an
unaltered ribose. Modifications within the ribose
moiety show a corresponding mass shift, e.g., neutral
loss of methylthioribose (162 Da) in 5=-deoxy-5=-
methylthioadenosine (MTA) [19, 27]. The generally
usly unknown urinary metabolites.
Figure 2. Processed 132 constant neutral loss trace (loss of ribose) of
TLC plate fraction 11 from a head and neck cancer patient. Abbre-
viations for analyzed metabolites: IAA-R: 1-ribosyl-imidazole-
4-acetic acid, acp3U: 3-(3-aminocarboxypropyl)-uridine, ncm5U:
5-carbamoylmethyluridine N6-SAR: N6-succinyloadenosine.
Numbered compounds already identified in previous studies [19,
25] (1  cytidine, 2  3-methylcytidine, 3  3,4-PCNR, 4 
2,5-PCNR, 5  1-methylinosine). Asterisks: currently under
investigation.
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MS2 enables the metabolite identification via the
remaining heterocycles, which are commercially
available more often than their ribosylated analogs.
Fragmentation patterns generated by auto LC-MS3
measurements are limited, especially when hypermodi-
fied structures are analyzed. Thus, we isolated selected
metabolites via semipreparative HPLC for syringe
pump infusion experiments, enabling MSn(n  4–6) anal-
ysis (Table 1). Beside the common neutral losses in CID
fragmentation processes, H2O and MeOH addition was
observed (Table 1, italic fragments). These neutral gains
have already been described in several mass spectro-
metric studies [29–31]. Impurities in the applied colli-
sion gas (H2O) as well as solvent molecules (MeOH,
H2O) passing from the ion source into the MS have been
discussed as possible sources for this phenomenon. We
were able to confirm the process of possible neutral gain
reactions in our ion trap mass spectrometer by analyz-
ing the N2,N2,7-trimethylguanosine standard in differ-
ent solvents via syringe pump infusion. The proposed
addition of residual methanol solvent molecules in the
MS4 fragmentation step of the semipreparatively iso-
lated N2,N2,7-trimethylguanosine (Table 1, no. 4, sam-
ple solved in methanol/ammonium formate buffer)
was no longer observable when the compound was
analyzed in pure acetonitrile.
The accurate masses determined by FTICR MS
experiments enabled the generation of molecular
formulae for the unknown ribosylated metabolites
(Table 2). We could narrow down the list of possible
molecular compositions by considering known prop-
erties of the analyzed compound class. A minimum of
five carbon atoms, four oxygens, and one nitrogen for
the labile C–N glycosidic bond as required for the
conjugated ribose moiety along with H and S were
chosen as constraints for mass analysis. As all com-
pounds show regular MS3 fragmentation behavior in
the IT MS measurements, we could exclude sodium
and potassium adducts, which usually do not show
MS3 fragmentation of the remaining heterocycle. The
generated molecular formulae were also used for
calculating the corresponding double-bond equiva-
lents (DBE) via formula (1), yielding additional hints
on the structural identity (double bonds, ring clo-
sures) of unknown metabolites.
DBE
(2n 2) (m k)
2
for CnHmOlNk (1)
Sulfur-oxygen double bonds (e.g., in sulfoxides) are not
considered in the resulting DBE value as the basic
elements generally contribute only in their lowest state
of valence. In some cases, the extremely low concentra-
tion and ion suppression effects by the PEG calibrant
precluded internal calibration, resulting in somewhat
poorer mass accuracy.Modified Nucleosides
With the presented analytical approach, we were able to
identify seven compounds, which turned out to be
modified nucleosides. In detail, these were the metab-
olites with m/z 302, 346, 398, 326, 333, 427, and 459
(Tables, no. 1–7). All mentioned compounds show a
CNL of 132 Da in the auto-LC IT MS3 screening runs,
indicating a nonmodified ribose moiety attached to the
corresponding heterocycle.
Compound m/z 302, occurring in TLC fraction 11,
showed consecutive expulsion of NH3 and CO, presum-
ably originating from a terminal carbamoyl-moiety and
HNCO pointing at a uridine-based structure. Consider-
ing the molecular formula [C11H16N3O7]
 obtained by
FT MS analysis, the metabolite could be identified as
5-carbamoylmethyluridine. Metabolite m/z 346 from
TLC fraction 11 showed characteristic fragmentation
behavior in IT MSn analysis. The MS4 step led to the loss
of a formic acid moiety (46 Da) and corresponding
carbon chain extended acids. In MS5, a loss of 43
(HNCO) was observed, pointing at uridine as basic
element. FT MS analysis revealed a molecular com-
position of [C13H20N3O8]
, verifying the proposed
ribonucleoside structure as 3-(3-aminocarboxypropyl)-
uridine. Both mentioned ribonucleosides have pre-
viously been reported by Chheda et al. as urinary
constituents [32, 33].
A metabolite with m/z 398 occurred primarily in TLC
fraction 2. The RNA database [26] lists two possible struc-
tures, namely 2-methylthio-N6-(cis-hydroxyiso-pentenyl)-
adenosine and 5-taurinomethyl-2-thiouridine. With the ob-
tained molecular formula suggestion [C16H24N5O5S]
 we
were able to exclude the latter. The molecular formula fit
the adenosine derivative. Additional hints were ob-
tained in the performed MSn analysis, showing charac-
teristic decays of C4H8O and C5H8O from the N
6-
substituted, hydroxylated carbon side chain in MS3 and
CH3SH from the methylthioadenosine scaffold in MS
4.
Combining this information, the metabolite could be
identified as 2-methylthio-N6-(cis-hydroxyiso-pentenyl)-
adenosine. The occurrence of this modified nucleoside
in human urine has not been verified previously.
A main component of the analyzed cis-diol metab-
olite pattern with m/z 326 was detected with peak
retention in TLC fraction 2. The measured mass/
charge ratio of 326.146067 could be attributed to a
molecular composition of [C13H20N5O5]
, exactly
matching that of the well-known urinary nucleoside
N2,N2,7-trimethylguanosine. Characteristic neutral
losses of (CH3)2NH and (CH3)2NCN in MS
3 support the
presumption of a hypermethylated guanosine scaffold.
As this modified nucleoside is commercially available,
we were able to verify the assigned structure via similar
fragmentation patterns and retention time.
Another metabolite with m/z 333 was detected in
TLC fraction 7. Three feasible nucleoside structures are
listed in the RNA database (5-oxyacetic acid methyl
ester-2-uridine, 5-carboxy-hydroxymethyl methyl ester-
Table 1. Fragmentation patterns of the isolated ribosylated metabolites via IT MSn analysis
No. MS MS2* MS3 MS4 MS5 MS6
1 302 (MH) 170 (BH) 153 (BH-NH3) 125 (153-CO) 100 (82H2O) 82 (100-H2O)
53 (100-H2O-CH2NH)
82 (125-HNCO)
125 (BH-NH3 -CO)
2 346 (MH) 214 (BH) 197 (BH-NH3) 151 (197-HCOOH)
125 (197-CH2CHCOOH)
113 (197-CHCCH2COOH) 96 (113-NH3)
70 (113-HNCO)
96 (197-C4H7NO2)
168 (BH-HCOOH)
3 398 (MH) 266 (BH) 248 (BH-H2O)
231 (?)
194 (BH-C4H8O) 165 (194-CH2NH) 150 (165-
●CH3)
138 (165-HCN)
182 (BH- C5H8O) 165 (182-NH3)
134 (182-CH3SH) 107 (134-HCN) 80 (107-HCN)
4 326 (MH) 194 (BH) 179 (BH-●CH3)
167 (149H2O) 181 (149CH3OH)
149 (167-H2O)
124 (167-HNCO) 142 (124H2O)
96 (124-CO)
69 (124-CO-HCN)
149 (BH-(CH3)2NH) 181 (149CH3OH)
167 (149H2O)
124 (BH-(CH3)2NCN) 156 (124CH3OH)
142 (124H2O)
96 (124-CO) 69 (96-HCN)
55 (96-CH3NC)
42 (96-CH2NCN)
5 333 (MH) 201 (BH) 169 (BH-CH3OH) 141 (169-CO) 114 (141-HCN)
100 (82H2O)
82 (141-HNCS)
141 (BH-CH3OCHO)
6 427 (MH) 295 (BH) 150 (BH-C5H7NO4) 133 (150-NH3) 124 (106H2O)
106 (133-HCN) 79 (106-HCN)
123 (150-HCN) 108 (123-●CH3)
96 (123-HCN)
94 (123-CH2NH)
94 (150-CH3NHCN) 67 (94-HCN)
7 459 (MH) 327 (BH) 208 (BH-C4H9NO3) 165 (208-HNCO) 150 (165-
●CH3) 123 (150-HCN)
138 (165-HCN)
182 (BH-C5H7NO4) 165 (182-NH3)
134 (182-CH3SH) 107 (134-HNC) 80 (107-HCN)
(Continued)
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Table 1. Continued
No. MS MS2* MS3 MS4 MS5 MS6
8 302 (MH) 170 (BH) 153 (BH-NH3) 135 (153-H2O) 107 (135-CO)
125 (107H2O)
107 (153-HCOOH)
126 (BH-CO2) 109 (126-NH3) 82 (109-HNC)
68 (109-CH3NC)
97 (126-CH2NH) 82 (97-
●CH3)
70 (97-HCN)
56 (97-CH3NC)
109 (BH-NH3-CO2) 82 (109-HCN)
68 (109-CH3NC)
9 288 (MH) 156 (BH) 110 (BH-HCOOH) 93 (110-NH3) 66 (93-HCN)
83 (110-HCN) 56 (83-HCN)
10 259 (MH) 127 (BH) 99 (BH-HCOOHH2O) 81 (99-H2O)
81 (BH-HCOOH) 54 (81-HCN)
99 (81H2O)
11 286 (MH) 154 (BH) 136 (BH-H2O) 95 (136-CH3CN) 68 (95-HCN)
112 (BH-CH2CO) 95 (112-NH3)
95 (BH-CH3CONH2)
12 300 (MH) 168 (BH) 150 (BH-H2O) 95 (150-C2H5CN) 68 (95-HCN)
112 (BH-C2H4CO) 95 (112-NH3)
95 (BH-C2H5CONH2)
13 314 (MH) 182 (BH) 164 (BH-H2O) 95 (164-C3H7CN) 68 (95-HCN)
112 (BH-C3H6CO) 95 (112-NH3)
95 (BH-C3H7CONH2)
14 328 (MH) 196 (BH) 178 (BH-H2O) 95 (178-C4H9CN) 68 (95-HCN)
112 (BH-C4H8CO) 95 (112-NH3)
95 (BH-C4H9CONH2)
15 342 (MH) 210 (BH) 192 (BH-H2O) 95 (192-C5H11CN) 68 (95-HCN)
112 (BH-C5H10CO) 95 (112-NH3)
95 (BH-C5H11CONH2)
16 362 (MH) 230 (BH) 212 (BH-H2O) 95 (212-C7H7CN) 68 (95-HCN)
112 (BH-C7H6CO) 95 (112-NH3)
95 (BH-C7H7CONH2)
(Continued)
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No. MS MS2* MS3 MS4 MS5 MS6
17 255 (MH) 123 (BH) 106 (BH-NH3) 78 (106-CO) 51 (78-HCN)
96 (78H2O) 78 (96-H2O) 51 (78-HCN)
68 (96-CO) 41 (68-HCN)
80 (BH-HNCO) 53 (80-HCN)
51 (80-NHCH2)
78 (BH-NH3 -CO) 51 (78-HCN)
18 212 (MH) 80 (BH) 53 (BH-HCN)
51 (BH-CH2NH)
19 228 (MH) 96 (BH) 78 (BH-H2O) 51 (78-HCN)
68 (BH-CO) 41 (96-HCN)
20 259 (MH) 127 (BH) 110 (BH- NH3) 128 (110H2O)
82 (110-CO) 55 (82-HCN)
128 (110 H2O)
21 384 (MH) 252 (BH) 234 (BH-H2O) 216 (234-H2O)
206 (234-CO)
192 (234-CH2CO) 148 (192-CO2) 137 (119H2O)
121 (148-HCN)
119 (148-CH2NH)
94 (148-CH2NCN)
162 (234-CO2-CO)
148 (234-CO2-CH2CO)
136 (234-C4H2O3)
206 (BH-HCOOH) 188 (206-H2O)
162 (206-CO2)
192 (BH-CH3COOH)
162 (BH-CO2-HCOOH) 135 (162-HCN) 136 (118H2O)
118 (135-NH3)
108 (135-HCN)
148 (BH-C3H4O4)
136 (BH-C4H4O4) 119 (136-NH3)
94 (136-NH2CN)
22 314 (MH) 136 (BH) 137 (119H2O)
119 (BH-NH3)
109 (BH-HCN)
94 (BH-NH2CN)
* The MS2 step is generally represented by the loss of 132 Da (decay of unmodified ribose) except for Compound 22, which shows neutral loss of 178 Da (decay of methylthioribose sulfoxide).
Italic: observed neutral gains, numbering consistent with Table 2.
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[26]. The first 2 compounds have identical molecular
formulae whereas that of Compound 3 differs. From the
FT MS analysis which indicated a molecular formula of
[C12H17N2O7S]
, the sulfur lacking uridine derivatives
could be excluded. Due to the exactly matching molec-
ular formula as well as a fitting and characteristic MSn
fragmentation pattern (e.g., decay of methanol in MS3,
decay of HNCS in MS5), the unknown metabolite could be
identified as 5-methoxycarbonylmethyl-2-thiouridine. The
occurrence o f this modified nucleoside in human urine
has also not been verified previously.
In TLC fraction 9, two metabolites with m/z 427 and
m/z 459 were detected and analyzed. For the first
compound an accurate mass/charge ratio of 427.157426
was determined via FT MS with a corresponding mo-
lecular formula of [C16H23N6O8]
. An RNA database
search offered two possible hypermodified nucleoside
structures with identical elemental composition: N6-
hydroxynorvalylcarbamoyladenosine and N6-methyl-
N6-threonylcarbamoyladenosine. Figure 3 exemplarily
shows the analytical benefit of higher fragmentation
steps in the analysis of complex ribonucleosides. The
unknown metabolite showed an almost unspecific frag-
Table 2. Accurate mass measurements and molecular formulae 
FTICR MS analysis
No. RT
Mass meas.
[MH]*
Molecular
formula [MH]
ppm
error** 
Modified nucleosides
1 7.0 302.09821 C11H16N3O7  0.22 (IC)
2 7.0 346.12442 C13H20N3O8  0.22 (IC)
3 40.0 398.148 C16H24N5O5S  3.9 (EC
4 41.5 326.1461 C13H20N5O5 0.53 (IC)
5 43.0 333.07506 C12H17N2O7S  0.13 (IC)
6 49.5 427.1574 C16H23N6O8 0.56 (IC)
7 50.0 459.1291 C16H23N6O8S  0.40 (IC)
Histidine metabolites
8 3.0 302.133 C12H20N3O6  5.2 (EC
9 3.5 288.117 C11H18N3O6  5.4 (EC
10 4.0 259.09249 C10H15N2O6 0.12 (IC)
11 10.0 286.13980 C12H20N3O5 0.17 (IC)
12 19.5 300.15545 C13H22N3O5 0.17 (IC)
13 30.0 314.1712 C14H24N3O5 0.46 (IC)
14 44.0 328.18659 C15H26N3O5  0.33 (IC)
15 51.5 342.2026 C16H28N3O5 0.80 (IC)
16 46.5 362.170 C18H24N3O5  1.7 (EC
Nicotinate/nicotinamide metabolites
17 4.0 255.0970 C11H15N2O5  2.1 (EC
18 5.0 212.0919 C10H14NO4 0.67 (IC)
19 7.0 228.08656 C10H14NO5  0.37 (IC)
Metabolites from the purine biosynthesis
20 10.0 259.10371 C9H15N4O5 0.066 (IC)
21 25.0 384.1153 C14H18N5O8 0.78 (IC)
Metabolite from the polyamine/methionine cycle
22 32.0 314.091755 C11H16N5O4S 0.013 (IC)
* Rounded values, reported up to the most significant decimal.
** IC: internal calibration, EC: external calibration, rounded values.
Italic: occurrence in human urine reported for the first time, bold: prev
Numbering consistent with Table 1. RT: retention time, DBE: double bmentation pattern in the auto-LC IT MS3 runs. Including theinformation of the MS4 step from syringe pump infusion IT
MSn experiments, it was possible to identify the basic hetero -
cycle of the analyzed compound since the MS4 spectrum was
identical to the MS3 spectrum of the commercially available
modified nucleoside N6-methyladenosine. Accordingly, the
unknown compound could be identified as N6-methyl-N6-
threonylcarbamoyladenosine (m6t6A). To the authors’ best
knowledge, this article describes for the first time the identi-
fication of this hypermodified nucleoside in human urine.
Another modified nucleoside with m/z 459, previously
unknown as constituent of human urine, could be identi-
fied in this study. Similar to the latter compound, a more
or less uncharacteristic pattern was observed i n t h e first
three fragmentation steps. An elemental composition of
[C16N23N6O8S]
 was obtained via FT MS analysis,
pointing at the sulfur analog of m6t6A, 2-methylthio-N6-
threonylcarbamoyladenosine. This was verified by MS n
analysis with the distinctive neutral losses of 43 Da
(HNCO) and 48 Da (CH3SH) in MS
4.
Histidine Metabolites
Many of the unknown compounds in the set of the
isolated urinary cis-diols turned out to be ribosylated
ration of the isolated ribosylated metabolites via
DBE Compound identified as
6 5-carbamoylmethyluridine
6 3-(3-aminocarboxypropyl)-uridine
8 2-methylthio-N6-(cis-hydroxyisopentenyl)-adenosine
7 N2,N2,7-trimethylguanosine
6 5-methoxycarbonylmethyl-2-thiouridine
9 N6-methyl-N6-threonylcarbamoyladenosine
9 2-methylthio-N6-threonylcarbamoyladenosine
5 3-ribosyl-1-methyl-L-histidinium
5 1-ribosyl-L-histidine
5 1-ribosyl-imidazole-4-acetic acid
5 1-ribosyl-N--acetylhistamine
5 1-ribosyl-N--propionylhistamine
5 1-ribosyl-N--butyrylhistamine
5 1-ribosyl-N--valerylhistamine
5 1-ribosyl-N--caproyllhistamine
9 1-ribosyl-N--phenylacetylhistamine
6 1-ribosyl-3-carbamoylpyridinium
5 1-ribosyl-pyridinium
5 1-ribosyl-3-hydroxypyridinium
5 1-ribosyl-4-carboxamido-5-aminoimidazole (AICA
riboside)
9 N6-succinyloadenosine
7 5’-deoxy-5’-methyl-thioadenosine sulfoxide
unknown metabolites.
quivalents.gene
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 histidine metabolites.
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occurred in the polar TLC fractions 11 and 12. With FT
MS analysis, the molecular formulae [C12H20N3O6]
and
[C11H18N3O6]
 were determined, indicating compound
m/z 302 to be a methylated analog of compound m/z 288.
The latter could be identified as 1-ribosyl-l-histidine via
the exactly fitting molecular composition and compar-
ison of MSn fragmentation with the l-histidine stan-
dard. Characteristic fragmentation moieties of the his-
tidine structure were the loss of NH3 and HCOOH from
the terminal side chain, and subsequent consecutive
HCN expulsion from the remaining imidazole scaffold.
The identified compound 1-ribosyl-l-histidine has al-
ready been isolated from urine of histidemic patients by
Imamura et al. [34].
Methylated histidines (1- and 3-methylhistidine)
have been analyzed by Piraud et al. via ESI-MS/MS
using a triple quadrupole mass spectrometer [35]. Dis-
tinctive fragmentation pathways have been reported for
the two position isomers, with that of 1-methylhistidine
being similar to the heterocycle of the unknown, meth-
ylated histidine riboside in this study. Identical frag-
mentation behavior could be confirmed by MSn analysis
of the 1-methylhistidine standard with our ion trap
system. To the authors’ best knowledge, the metabolite
3-ribosyl-1-methyl-l-histidinium identified has not
been described previously in literature.
A compound with m/z 259 (Tables, no. 10), occurring in
TLC fractions 11 and 12 has already been analyzed in our
research group by means of combined IT MS and LC-TOF
MS measurements [24]. It had been identified as the
histamine metabolite 1-ribosyl-imidazole-4-acetic acid and
was confirmed in the present study with a lower ppm
error and MSn fragmentation comparison with the com-
mercially available standard imidazole-4-acetic acid.
A series of metabolites with a consecutive mass shift
of 14 Da (m/z 286, 300, 314, 328, 342; Tables, no. 11–15)
Figure 3. IT MS4 fragmentation pathway for
carbamoyladenosine. MS4 spectrum is identicaand similar fragmentation behavior was detected inauto-LC-IT MS3 runs of the TLC fractions 1–3. These
compounds all showed ribose decay in the MS2 step as
well as water elimination and two characteristic, basic
fragments m/z 112 and 95 in the MS3 step.
As a primary result from the MS3 fragmentation
pathways, the analyzed compounds presumably share
a basic structural element (m/z 112 and 95) and a side
chain elongated by methylene insertion. This was con-
sistent with the chromatographic properties, showing
an increasing retardation with increasing carbon chain
length and thus decreasing polarity on the applied
RP-18 column (Figure 4). FT MS measurements con-
firmed the hypothesis of a methylene mass shift of 14
Da via molecular formula suggestion based on accurate
mass determination (Table 2).
The most obvious endogenous compounds showing a
linear carbon chain extension are the fatty acids. In literature,
no cross-linked reactions between RNA metabolites and
fatty acids are described. Screening the human histidine
metabolism in the KEGG PATHWAY Database (http://
www.genome.jp/kegg/pathway.html), we found a com-
pound with fitting properties, concerning the possible het-
erocycle of the ribosylated compound m/z 286. The
metabolite 4--acetylaminoethyl-imidazole (trivial name:
N--acetylhistamine) is formed via addition of acetic acid to
the histamine scaffold. The corresponding elemental
composition [C7H12N3O]
was identical with that of the
unknown compound m/z 286 [C12H20N3O5]
 minus the
ribose moiety [-C5H8O4]. Final confirmation of the pro-
posed structure was achieved via comparative MSn
fragmentation with the commercially available hetero-
cycle standard N--acetylhistamine. Combining the ob-
served mass shift of 14 Da proved in FT MS measure-
ments of m/z 286, 300, 314, 328, and 342 with the
expulsion of an increasing side-chain moiety (286 
acetonitrile, 300  propiononitrile, 314  butyronitrile,
328  pentanonitrile, 342  hexanonitrile) in the MS4
identified compound N6-methyl-N6-threonyl-
th MS3 spectrum of N6-methyladenosine.thestep (see Table 1), the metabolite series was structurally
1510 BULLINGER ET AL. J Am Soc Mass Spectrom 2008, 19, 1500–1513elucidated as ribosylated histamines, conjugated to lin-
ear short-chain fatty acids at the N-position (see Figure
1). A proposal for the proceeding fragmentation mech-
anisms is shown in Scheme 1. With the basic structure
identified, the biochemical origin was unknown since
no chain elongation of acetylhistamine is known in
human metabolism. However, a formation of homolo-
gous short-chain fatty acid (C2-C4)-histamine conju-
gates (N--acetylhistamine, N--propionylhistamine,
N--butyrylhistamine) has been reported in context
with the activity of intestinal bacteria [36]. These me-
tabolites have been detected in human urine with a
suggested qualitative and quantitative dependency of
the measured excretory pattern upon intestinal amino
acid transport, composition of the bacterial flora, and
dietary aspects (e.g., fermentation of dietary fiber).
The corresponding ribosylated conjugates have not
been described previously in literature. There is no
additional information about possible processes of re-
sorption and ribosylation. This should be the subject of
further investigations. The probable bacterial origin of
these metabolites led to their exclusion from our ongo-
ing cancer biomarker studies.
Related to but not exactly consistent with the meth-
ylene shift properties of the last-mentioned histamine
Figure 4. Metabolite series of ribosylated hi
showing increasing retardation on RP-18 colu
fragmentation patterns.metabolites was a compound with m/z 362 (Tables, no.16), found in TLC fraction 4. The fragmentation path-
way of this metabolite also showed water elimination
and the two basic fragments m/z 112 and 95, suggesting
the similar basic structure of a histamine riboside con-
jugated to a carbon side chain. An elemental composi-
tion of [C18H24N3O5]
 was obtained possessing nine
double-bond equivalents (compounds 286–342 all have
5 DBE). Considering the molecular formula and the
DBE value, the only possible structure could be a
benzene ring system (four DBE) in the conjugated
carbon side chain. A structure matching the required
properties is phenylacetic acid, also known as a bacte-
rial degradation product of nonabsorbed phenylalanine
in the human intestinal lumen [37]. The combined mass
spectrometric data confirmed the conjugation of this
presumably bacterial metabolite to a histamine scaffold
to give rise to the previously unknown urinary com-
pound 1-ribosyl-N--phenylacetylhistamine.
Nicotinate/Nicotinamide Metabolites
A main component of the urinary cis-diol metabolite
pattern with m/z 255 (Tables, no. 17) could be detected
in nearly all fractions of the TLC separation. FT MS
measurements revealed a molecular composition of
ine–fatty acid conjugates (Tables, no. 11–15),
and similar properties in the correspondingstam
mn[C11H15N2O5]
. Consecutive neutral loss of NH3 and
H5 (m
1511J Am Soc Mass Spectrom 2008, 19, 1500–1513 METABOLITE IDENTIFICATION VIA FT MS AND IT MSCO in IT MS3 could be attributed to the cleavage of a
terminal carbamoyl moiety. The second analyzed frag-
mentation pathway via expulsion of HNCO in MS3 sub-
sequently showed distinctive double elimination of the pyri-
dine nitrogen as HCN and NHCH2, respectively. A
compound matching the obtained MS data is 1-ribosyl-3-
carbamoylpyridinium, also known as ribosylated nicotin-
amide. IT MS analysis of the nicotinamide base standard
verified this presumption. Morris et al. first reported the
isolation of this metabolite from human urine [38].
In the TLC fractions 3 and 4, two metabolites with
m/z 212 and 228 (Tables, no. 18, 19) were detected. Both
compounds show the common neutral loss of 132 in the
MS2 step and were semipreparatively isolated for
further mass spectrometric analysis. The corresponding
elemental compositions were [C10H14NO4]
 and
[C10H14NO5]
, respectively, and argue for m/z 228
to be the oxidized counterpart of m/z 212. The latter
could be identified as the previously unknown 1-ribosyl-
Scheme 1. Fragmentation mechanism proposa
fatty acid conjugates (Tables, no. 11–16); R 
-(CH2)2CH3 (m/z 328), -(CH2)3CH3 (m/z 342), -C6pyridinium via the generated molecular formula with aresulting DBE value of 5 as well as comparative MSn
analysis with the pyridine standard. MSn analysis of
compound m/z 228 showed elimination of carbon mon-
oxide in MS3 and loss of HCN in the MS4 step, pointing
to a ribosylated hydroxypyridine structure with un-
known position (ortho, meta or para) of the hydroxy
function. Comparative MSn studies of the hydroxypyri-
dine standards available with the heterocycle of m/z 228
led to a characteristic distinction between the three
possible position isomers via differences in the relative
intensities of the two fragmentsm/z 78 and 68. As the MS2
spectrum of 3-hydroxypyridine exactly fit theMS3 spectrum
of the ribosylated hydroxypyridine (Figure 5), compound
m/z 228 could be identified as the previously unknown,
urinary metabolite 1-ribosyl-3-hydroxypyridinium.
Purine Biosynthesis
Two compounds deriving from the purine biosynthesis
the metabolite series of ribosylated histamine–
m/z 286), -CH3 (m/z 300), -CH2CH3 (m/z 314),
/z 362).l for
-H (could be identified in this study. The metabolite 1-ribosyl-
r), an
1512 BULLINGER ET AL. J Am Soc Mass Spectrom 2008, 19, 1500–15134-carboxamido-5-aminoimidazole (m/z 259; Tables, no.
20), a well-known urinary constituent [39], occurred in
TLC fraction 9. With FT MS analysis, the fitting molec-
ular formula suggestion of [C9H15N4O5]
was obtained.
MSn studies showed consecutive elimination of NH3,
CO, and HCN moieties after the common cleavage of
the C–N glycosidic bond. Fragmentation behavior and
retention time were identical with the commercially
available standard compound and led to the unambig-
uous structural elucidation of the commonly named
AICA riboside.
A metabolite with m/z 384 (tables, no. 21) was
primarily detected in the TLC fractions 10 and 11. MSn
studies of this compound resulted in extensive frag-
mentation patterns, marked by complex expulsion of car-
bon oxides and carboxylic acid residues. The cleavage of a
C4H4O4-moiety in MS
3 resulted in a fragment with m/z 136,
which subsequently fragmented under elimination of NH3
andNH2CN. As the latter fragmentation pathway is charac-
teristic for the adenine base (m/z 136), we suggested the
unknown compound to be the hypermodified adeno-
sine structure, N6-succinyloadenosine. This was con-
firmed by the obtained molecular composition of
[C14H18N5O8]
 and comparative MSn analysis with the
commercially available, monophosphosphorylated an-
alog adenylosuccinic acid. Chheda already isolated and
characterized N6-succinyloadenosine from urine of co-
lon cancer patients and healthy volunteers [40].
Methionine/Polyamine Cycle
An unusual neutral loss (178 Da) was observed in MS2
of a metabolite with m/z 314 (tables, no. 22) in TLC
fraction 3, pointing to a modified ribose structure
attached to the heterocycle. The latter could be identi-
fied as adenine via the characteristic fragmentation
Figure 5. Identification of position isomer 3
previously unknown, urinary metabolite 1-ribos
relative intensities of fragments 78 (loss of watepattern, including the loss of NH3, HCN, and NH2CN.The metabolite MTA, a byproduct of the polyamine
biosynthesis [27], shows similar properties. This com-
pound loses the methylthioribose moiety in MS2 (162
Da), resulting in the protonated adenine nucleobase.
Combining the oxygen shift in the neutral loss values
(162  178) with the obtained molecular formula
[C11H16N5O4S]
, we were able to identify the metabolite
as the already known sulfoxide analog of MTA, 5=-deoxy-
5=-methyl-thioadenosine sulfoxide (MTA-SO) [41].
Conclusions
This work demonstrates the potential of combined IT
MSn and FT MS analysis as a powerful tool for struc-
tural elucidation of urinary metabolites. In this basic,
first-step approach of our ongoing metabolic profiling
project, we were able to identify 22 compounds deriv-
ing from different metabolic pathways such as RNA
metabolism, histidine metabolism, nicotinate/nicotin-
amide metabolism, purine biosynthesis, and methio-
nine/polyamine cycle. The occurrence of four modified
nucleosides is described for the first time in human urine.
Also, a previously unknown series of ribosylated histamines
conjugated to homologues short-chain fatty acids and phe-
nylacetic acid, respectively, were revealed in this study.
The compounds 1-ribosyl-3-hydroxypyridinium, 1-ribosyl-
pyridinium, and 3-ribosyl-1-methyl-l-histidinium were
found as novel urinary constituents. The identification of
these unknown compounds may lead to a reinvestigation
of the corresponding metabolic pathways. It has to be
pointed out that none of the identified metabolites from
this study showed a specific, tumor-related occurrence
as they were present in all screened urine samples and
even in previously analyzed urines from healthy vol-
unteers. However, structural elucidation enables the
constitution of a more reliable urinary metabolic profile
oxypyridine as heterocycle compound of the
ydroxypyridinium (m/z 228) via comparison of
d 68 (loss of CO) in IT MSn analysis.-hydr
yl-3-hdue to the assignment and subsequent exclusion of
1513J Am Soc Mass Spectrom 2008, 19, 1500–1513 METABOLITE IDENTIFICATION VIA FT MS AND IT MSmetabolites with presumably nonhuman origin. Due
to the interconnectivity of the considered pathways,
tumor-related perturbations in the RNA subset poten-
tially provoke implications on the others and vice versa.
Consequently, the second step of our continuing meta-
bolic profiling project will be the utilization of bioinfor-
matic classification algorithms for quantitative pattern
recognition of urinary ribosylated metabolites.
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